RecruitingNot ApplicableNCT07817147

CREO - Microwave Ablation Feasibility Study

Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer

Sponsor

Banner Health

Enrollment

75 participants

Start Date

Feb 19, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Cancer Stage IV Liver Cancer (Locally Advanced or Metastatic)Liver Cancer Stage IV Pancreatic Cancer Non-resectable Liver Cancer Stage IIIa Liver Cancer Stage IIIb Liver Cancer Stage IIIc Pancreatic Cancer Stage III

Summary

The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying EUS-Guided MWA Device for people with liver cancer (locally advanced or metastatic), liver cancer stage iiia, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEUS-Guided MWA Device

The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.